THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (OTCMKTS:TSOI) Files An 8-K Other Events
Item 8.01 Other Events.

On March 29, 2017, the United States Patent and Trademark Office (the “USPTO”) accepted U.S. Application No. 62/478532 titled “Stimulation of Immunity to Tumor Stem Cell Specific Proteins by Peptide Immunization”.

Item 9.01 Financial Statements and Exhibits.

Exhibit Index

(10.1) Exclusive Patent License Agreement between Therapeutic Solutions International, Inc., and Emvolio, Inc.

(99.1) Press release dated April 10, 2017, issued by Therapeutic Solutions International, Inc.

About THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (OTCMKTS:TSOI)

Therapeutic Solutions International, Inc. (TSOI) is focused on immune modulation for the treatment of several specific diseases. TSOI is developing a range of immune-modulatory agents to target certain cancers, improve maternal and fetal health, fight periodontal disease, and for daily health. Its ProJuvenol is a blend of complex anti-aging ingredients to help promote cellular rejuvenation and healthy functionality for everyday living, based upon pterostilbene. Its subsidiary, OmniBiome, Inc., is focused on therapeutic/Rx approaches to either utilize or intervene with the systemic effects of the vaginal, lactal-duct and oral microbiomes for improving maternal healthcare and resulting birth outcomes. MolecuVax, Inc. is a subsidiary of the Company. TSOI markets approximately two other nutraceuticals, such as T-Rx, a testosterone booster, and Vital Female, an estrogen booster.

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (OTCMKTS:TSOI) Recent Trading Information

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (OTCMKTS:TSOI) closed its last trading session 00.00000 at 0.00910 with 115,450 shares trading hands.